ST nano

Frbiz Site


Recently, Debiotech and STMicroelectronics have announced the signing of a manufacturing and selling a unique miniaturized insulin-delivery pump of a strategic cooperation agreement. The pump is a nano-based microfluidic MEMS (microelectromechanical systems) technology, innovative concept that is a tiny pump to be mounted on a disposable skin patch to provide continuous infusion of insulin diabetes. The Nanopump will enable substantial advancements in the availability, treatment efficiency and quality of life of diabetic patients. The original technology was awarded the Swiss Technology Award in 2006, today signed an agreement to make it closer to the goal of industrialization.






microwave toaster combination


  Insulin pump therapy or continuous subcutaneous insulin (CSII) can be replaced several times a day insulin infusion to injection alone, more and more people are optimistic this therapy. In accordance with CSII therapy, diabetic patients need to connect a programmable syringe pump, injection pump and connected to a storage medium irrigation, storage of insulin from the subcutaneous tissue infused into the body within a day of continuous infusion is more like the natural secretion of insulin the pancreas process.
gprs terminal








The highly miniaturized disposable insulin pump combines Debiotech ST insulin infusion technology and mass manufacturing microfluidic chip production capacity. Microfluidic technology can electronically control the number of very small liquid flows. The injection pump marked the CSII therapy in the development and applications a big step forward, and the cutting-edge technology will also be applied to other biomedical applications.








Today, existing insulin pumps are about the size of a pager. The new manufactured by ST Debiotech miniaturized MEMS products, size is about one-fourth of the existing injection pump to the skin patch form of wear in the human body, the human eye could barely see it there. Patients need to pay attention to the last injection pump mounting location is appropriate, even to pump hidden under clothing, new products, small size frees patients to worry about.








In addition, the use of MEMS technology, nano-pumps can precisely control the medical requirements of the insulin doses. Dose level of precision is a critical factor in efficacy, but also help reduce the negative effects of drugs long-term infusion. Nano-liquid infusion pump control accuracy can be at the nanoliter level, very close to the physiological delivery of insulin. The product can prevent overdose, injection pump testing of pharmaceutical delivery, occlusion, air bubbles and other potential failures, in order to further protect patients. In addition, as a large-scale semiconductor manufacturing techniques with disposable products, the nano-syringe pump based MEMS the cost is very low, the patient or the health care system without having to pay existing pumps solutions common front investment.








This development by the Debiotech, ST industrialization marked insulin pump microfluidic MEMS technology was first applied to the diabetes treatment. Nano Functional samples have already been produced, the two partners expect the market after 2008 as a designated supply the form of a disposable cartridge sales of a fully industrialized product. Debiotech will be taken to the medical device market authorization in the form of the major manufacturers sell their products.








The industrialization of new products will make full use of ST in the market, the accumulation of biochemical manufacturing experience. ST's Microfluidic Division include other bio-technology projects at present mainly used for the detection of sepsis and Avian flu In-Check platform for on-chip experiments.








"ST is constantly strengthening its semiconductor manufacturing process applications, and microfluidic biotech applications continue to accumulate experience, which as we extend the lives of millions worldwide provides the possibility," ST Vice President and microfluidic Control Products Division general manager AntonHofmeister said, "and led the field of chemical and biological application development company Debiotech cooperation, we mainly responsible for nano insulin pump in production, the project's goal is to completely break the limit of diabetes treatment."








"Our collaboration with ST represents the project in the manufacture of nano-injection pump to move a big step, so that new products can match the cost with one-time items in the huge market on the production and sales. ST is the world's leading The MEMS manufacturers, we are very pleased to cooperate with the ST, we will a truly innovative products to patients with diabetes, for this century, one of the most serious disease of diabetes, to provide a new treatment. "DebiotechSA president CEO Dr. FredericNeftel.








Supplement Currently about 2.5 million people worldwide infected with diabetes, along with population growth, aging and lifestyle changes, is expected in the next decade the number of patients will continue to increase. Without proper treatment, diabetes can cause cardiovascular disease, kidney failure, blindness and nerve damage until death. Diabetes in Western countries is one of the leading cause of death.








Insulin pump therapy market is booming: It HSBC1, in 2009, the global market is expected to insulin pump therapy from 2004 to 8 billion U.S. dollars to 1.6 billion.